53984-98-8

Usage

Uses

Used in Pharmaceutical Industry:
2-CYANO-N-(2,6-DIMETHYL-PHENYL)-ACETAMIDE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its role in this industry is crucial for creating compounds that can address a range of health conditions.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, 2-CYANO-N-(2,6-DIMETHYL-PHENYL)-ACETAMIDE serves as an intermediate in the production of agrochemicals, potentially aiding in the creation of substances that can protect crops and enhance agricultural productivity.
Used as an Anticonvulsant Agent:
2-CYANO-N-(2,6-DIMETHYL-PHENYL)-ACETAMIDE is used as an anticonvulsant in pre-clinical studies, where it has shown promise in managing conditions like epilepsy by reducing the frequency and severity of seizures.
Used as an Analgesic Agent:
In the realm of pain management, 2-CYANO-N-(2,6-DIMETHYL-PHENYL)-ACETAMIDE is utilized as an analgesic agent, demonstrating potential to alleviate pain effectively in various conditions.
Used in Neurodegenerative Disease Treatment:
2-CYANO-N-(2,6-DIMETHYL-PHENYL)-ACETAMIDE has also been indicated for use in the treatment of neurodegenerative diseases, where it may offer therapeutic benefits by potentially slowing disease progression or managing symptoms.

InChI:InChI=1/C11H12N2O/c1-8-4-3-5-9(2)11(8)13-10(14)6-7-12/h3-5H,6H2,1-2H3,(H,13,14)

Upstream product

• 32433-61-7 2-bromo-N-(2,6-dimethyl-phenyl)-acetamide 
• 151-50-8 potassium cyanide 
• 372-09-8 cyanoacetic acid 
• 87-62-7 2,6-dimethylaniline 
• 16130-58-8 cyanoacetic acid chloride 
• 105-34-0 methyl 2-cyanoacetate 

Downstream Products

• 146494-83-9 2-Amino-4-(2,6-dimethyl-phenyl)-3-oxo-1,4-diaza-spiro[4.5]decane-2-carboxylic acid amide 
• 133550-51-3 AG 531 
• 512173-12-5 2-amino-3-{[(2,6-dimethylphenyl)amino]carbonyl}-1,8-naphthyridine 
• 512173-15-8 3-{[(2,6-dimethylphenyl)amino]carbonyl}-2-[(ethoxycarbonyl)amino]-1,8-naphthyridine 
• 138574-70-6 4-(2,6-Dimethyl-phenyl)-3-oxo-1,4-diaza-spiro[4.5]dec-1-ene-2-carboxylic acid amide 
• 1370047-82-7 N-(2,6-dimethylphenyl)-2,5-dihydro-2-imino-4,5,5-trimethylfuran-3-carboxamide 
• 1370047-84-9 N-(2,6-dimethylphenyl)-2-imino-4-methyl-1-oxaspiro[4.5]dec-3-ene-3-carboxamide 
• 1370047-85-0 N-(2,6-dimethylphenyl)-2,5-dihydro-4,5,5-trimethyl-2-oxofuran-3-carboxamide 
• 1370047-87-2 N-(2,6-dimethylphenyl)-4-methyl-2-oxo-1-oxaspiro[4.5]dec-3-ene-3-carboxamide 
• 1370047-90-7 N-(2,6-dimethylphenyl)-2,5-dihydro-2-imino-4,5,5-trimethylfuran-3-carboxamide hydrochloride 
• 1370047-92-9 N-(2,6-dimethylphenyl)-2-imino-4-methyl-1-oxaspiro[4.5]dec-3-ene-3-carboxamide hydrochloride 
• 951900-54-2 5-amino-N-(2,6-dimethylphenyl)-1-(4-fluorophenyl)-1H-1,2,3-triazole-4-carboxamide 

Relevant academic research and scientific papers

ATP competitive inhibitors of d-alanine-d-alanine ligase based on protein kinase inhibitor scaffolds

d-Alanine-d-alanine ligase (DDl) is an essential enzyme in bacterial cell wall biosynthesis and an important target for developing new antibiotics. Here, we describe a new approach to identify new inhibitor scaffolds for DDl based on similarity in the ATP

Alternating copolymerization of carbon dioxide and cyclohexene oxide and their terpolymerization with lactide catalyzed by zinc complexes of N,N ligands

For the alternating copolymerization of CO2 and cyclohexene oxide, a variety of zinc acetate complexes with new aminoimidoacrylate ligands has been synthesized and tested as catalysts. All complexes catalyzed the reaction and structure-activity

Alternating copolymerization of cyclohexene oxide and CO2 catalyzed by zinc complexes with new 3-amino-2-cyanoimidoacrylate ligands

New 3-amino-2-cyanoimidoacrylate ligands with varying steric demands have been synthesized. Zinc acetate complexes of these ligands catalyze the copolymerisation of CO2 and cyclohexene oxide, showing high activities (TOF up to over 200 h -1).

Tyrphostins. 2. Heterocyclic and α-Substituted Benzylidenemalonitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases

We have previously described a novel series of low molecular weight protein tyrosine kinase inhibitors which we named tyrphostins.The characteristic active pharmacophore of these compounds was the hydroxy-cis-benzylidenemalonitrile moiety.In this article we describe three novel groups of tyrphostins: (i) one group has the phenolic moiety of the cis-benzylidenemalononitrile replaced either with other substituted benzenes or with heteroaromatic rings, (ii) another is a series of conformationally constrained derivatives of hydroxy-cis-benzylidenemalononitriles in which the malononitrile moiety is fixed relative to the aromatic ring, and (iii) two groups of compounds in which the position trans to the benzenemalononitrile has been substituted by ketones and amides.Among the novel tyrphostins examined we found inhibitors which discriminate between the highly homologous EGF receptor kinase (HER1) and ErbB2/neu kinase (HER2).These findings may lead to selective tyrosine kinase blockers for the treatment of diseases in which ErbB2/neu is involved.